A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
Recruiting in Palo Alto (17 mi)
+345 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: AstraZeneca
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
Eligibility Criteria
Inclusion Criteria
Provision of signed informed consent/ paediatric assent (if applicable) prior to any study specific procedures including medication withdrawal
Male or Female, ≥12 years of age
Documented clinical diagnosis of asthma for at least 1 year prior to Visit 2
See 3 more
Treatment Details
Interventions
- budesonide pMDI (Corticosteroid)
- Symbicort pMDI (Corticosteroid)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment1 Intervention
Symbicort
Group II: 2Active Control1 Intervention
budesonide
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Research SiteKansas City, MO
Research SiteSt Louis, MO
Research SiteBend, OR
Research SiteBryn Mawr, PA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
AstraZenecaLead Sponsor